SEATTLE GENETICS RECEIVES U.S. PATENTS FOR SGN-40 PROGRAM

Seattle Genetics has announced that the U.S. Patent and Trademark Office has issued two patents relating to the company's SGN-40 program.

The patents claim composition of matter and methods of using anti-CD40 antibodies for the treatment of cancer. Seattle Genetics is currently conducting Phase I clinical trials of SGN-40, an anti-CD40 antibody, in multiple myeloma and non-Hodgkin's lymphoma. The company plans to initiate an additional Phase I study in chronic lymphocytic leukemia during the first half of 2005.